F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients

330
28
Favorite

F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients

Benzinga2021-08-12

F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.
The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).
FS118 is a bispecific antibody targeting LAG-3 and PD-L1.
In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.
F-Star ended the quarter with cash and cash equivalents of $81.6 million.
Price Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

330

Report

Comment（28）

Dbw
·2021-08-13
Like and comment pls
Reply
2
Report
1nu
·2021-08-13
help me like and comment :)
Reply
5
Report
Fold Replies
- FunnyFun:
  Ok
  2021-08-13
  Reply
  Report
- Singman:
  pls like too
  2021-08-13
  Reply
  Report
保升龙
·2021-08-13
Ok
Reply
4
Report
Fold Replies
- JANICELSJ:
  Ok
  2021-08-13
  Reply
  Report
Syww
·2021-08-13
[Strong] [Strong]
Reply
2
Report
Sonson89
·2021-08-13
K
Reply
2
Report
飙高音
·2021-08-13
Ok
Reply
3
Report
JimmyLZH
·2021-08-13
??
Reply
3
Report
xremy
·2021-08-13
Another Big... Upupup..
Reply
3
Report
white_fangg
·2021-08-13
Like and comment
Reply
3
Report
Fold Replies
- Pplymm:
  Done. pls like back
  2021-08-13
  Reply
  Report
- alexpee98:
  yes babe
  2021-08-13
  Reply
  Report
pfudor
·2021-08-13
Ok
Reply
2
Report
Andtendo
·2021-08-13
Like and comment please
Reply
5
Report
Fold Replies
- Pplymm:
  Done. pls like back
  2021-08-13
  Reply
  Report
lingnh
·2021-08-13
Ok
Reply
5
Report
losty
·2021-08-13
Like please
Reply
3
Report
Fold Replies
- Jaaaaaaa:
  B
  2021-08-13
  Reply
  Report
liangwee888
·2021-08-13
comment
Reply
3
Report
Fold Replies
- MamaProfit:
  no comment
  2021-08-13
  Reply
  Report
PooYen
·2021-08-13
Please like. Thanks [Happy] [Happy] [Happy]
Reply
5
Report
Fold Replies
- Pplymm:
  Done. pls like back
  2021-08-13
  Reply
  Report
- eddnesb:
  like pls
  2021-08-13
  Reply
  Report
- VenomJames:
  Sure
  2021-08-13
  Reply
  Report
J90
·2021-08-13
Help
Reply
2
Report
Fold Replies
- liangwee888:
  ok
  2021-08-13
  Reply
  Report
J90
·2021-08-13
Yaaaa
Reply
5
Report
Fold Replies
- Xue91:
  Yahhhh
  2021-08-13
  Reply
  Report
Andrew210782
·2021-08-13
Like
Reply
6
Report
June_C
·2021-08-13
Wiooo
Reply
7
Report
MoreNmore
·2021-08-13
Like
Reply
Like
Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2158268958?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-08-12 23:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2158268958","market":"us","top_or_hot":-1,"title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","media":"Benzinga","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n2021-08-12 23:12 北京时间&nbsp;&nbsp;&nbsp;<strong>Benzinga</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker ...</p>\n\n<a href=\"None\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FSTX","symbol_name":"F-star Therapeutics, Inc. ","start_time":0,"source_url":null,"article_id":"2158268958","we_media_id":"1052270027","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","pubTimestamp":1628781141,"sourceInfo":null,"weMediaInfo":{"media_name":"Benzinga","introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"summary":"\n","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"translate_title":"F-STAR的FS118开发计划将检查点幼稚癌症患者包括在内","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FSTX":0.9},"content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":894375487,"gmtCreate":1628809618149,"gmtModify":1676529859054,"author":{"id":"3574901428369611","authorId":"3574901428369611","name":"Dbw","avatar":"https://static.tigerbbs.com/b2b540981c00cc0005e6241f782bd3c5","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":1,"crmLevelSwitch":0,"idStr":"3574901428369611","authorIdStr":"3574901428369611"},"htmlText":"Like and comment pls","listText":"Like and comment pls","text":"Like and comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894375487","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894344901,"gmtCreate":1628809021803,"gmtModify":1676529858683,"author":{"id":"3577610430427001","authorId":"3577610430427001","name":"1nu","avatar":"https://static.tigerbbs.com/15789a74f3eb14371af59c44a8f71041","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577610430427001","authorIdStr":"3577610430427001"},"htmlText":"help me like and comment :)","listText":"help me like and comment :)","text":"help me like and comment :)","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/894344901","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510239,"gmtCreate":1628809392733,"gmtModify":1663232297526,"authorId":3581664026895626,"author":{"id":3581664026895626,"idStr":"3581664026895626","authorId":3581664026895626,"name":"FunnyFun","avatar":"https://static.tigerbbs.com/e07aca58746125ec6ef6115042d363e9","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.01.12","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894344901,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":5510254,"gmtCreate":1628809470751,"gmtModify":1663232297330,"authorId":3575125836760247,"author":{"id":3575125836760247,"idStr":"3575125836760247","authorId":3575125836760247,"name":"Singman","avatar":"https://static.tigerbbs.com/d770feb757705f2d631d2d5f381ae07b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894344901,"type":1,"supId":0,"prevId":0,"content":"pls like <u>too</u>","text":"pls like <u>too</u>","html":"pls like <u>too</u>"}],"langContent":"EN"},{"id":894349901,"gmtCreate":1628808521103,"gmtModify":1676529858505,"author":{"id":"3579730769631306","authorId":"3579730769631306","name":"保升龙","avatar":"https://static.tigerbbs.com/e01d8942aa5f0e60c802ba77bcd46430","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579730769631306","authorIdStr":"3579730769631306"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894349901","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510683,"gmtCreate":1628811258294,"gmtModify":1663232299229,"authorId":3579777216498074,"author":{"id":3579777216498074,"idStr":"3579777216498074","authorId":3579777216498074,"name":"JANICELSJ","avatar":"https://community-static.tradeup.com/news/22bb420ffd42fa4b0fc986abd53b711f","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894349901,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"}],"langContent":"EN"},{"id":894340494,"gmtCreate":1628808497618,"gmtModify":1676529858495,"author":{"id":"4087953623473280","authorId":"4087953623473280","name":"Syww","avatar":"https://static.tigerbbs.com/eb83576edbcfb98efcb33d606f168221","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4087953623473280","authorIdStr":"4087953623473280"},"htmlText":"[Strong]&nbsp;[Strong]&nbsp;","listText":"[Strong]&nbsp;[Strong]&nbsp;","text":"[Strong] [Strong]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894340494","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894357765,"gmtCreate":1628808471257,"gmtModify":1676529858479,"author":{"id":"3577445690140943","authorId":"3577445690140943","name":"Sonson89","avatar":"https://static.tigerbbs.com/bb78553b48c28648b70634c067b819ec","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":0,"idStr":"3577445690140943","authorIdStr":"3577445690140943"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894357765","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894357401,"gmtCreate":1628808469903,"gmtModify":1676529858470,"author":{"id":"3582709856792743","authorId":"3582709856792743","name":"飙高音","avatar":"https://static.tigerbbs.com/475b76d560816b91289272c06ae8dfff","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582709856792743","authorIdStr":"3582709856792743"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894357401","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894354323,"gmtCreate":1628808359562,"gmtModify":1676529858439,"author":{"id":"3586863844711073","authorId":"3586863844711073","name":"JimmyLZH","avatar":"https://static.tigerbbs.com/7ecc6de8a47b65c54bcbdca5fe23b697","vip":1,"hat":"https://static.tigerbbs.com/4c5ceab71416b120bab4604c0754b52a","crmLevel":2,"crmLevelSwitch":0,"idStr":"3586863844711073","authorIdStr":"3586863844711073"},"htmlText":"??","listText":"??","text":"??","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894354323","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894353468,"gmtCreate":1628807943254,"gmtModify":1676529858302,"author":{"id":"4091425725265930","authorId":"4091425725265930","name":"xremy","avatar":"https://static.tigerbbs.com/eed128399f7a5afff5ef683e5991f030","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4091425725265930","authorIdStr":"4091425725265930"},"htmlText":"Another Big... Upupup..&nbsp;","listText":"Another Big... Upupup..&nbsp;","text":"Another Big... Upupup..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894353468","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894322882,"gmtCreate":1628807489946,"gmtModify":1676529858155,"author":{"id":"3587098012837997","authorId":"3587098012837997","name":"white_fangg","avatar":"https://static.tigerbbs.com/7bb054ebcc34da2e4209120935bb5774","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3587098012837997","authorIdStr":"3587098012837997"},"htmlText":"Like and comment","listText":"Like and comment","text":"Like and comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/894322882","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510169,"gmtCreate":1628808998479,"gmtModify":1663232297349,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894322882,"type":1,"supId":0,"prevId":0,"content":"Done. pls like back ","text":"Done. pls like back ","html":"Done. pls like back "},{"id":5509988,"gmtCreate":1628807801641,"gmtModify":1663232295846,"authorId":3562397124560737,"author":{"id":3562397124560737,"idStr":"3562397124560737","authorId":3562397124560737,"name":"alexpee98","avatar":"https://static.tigerbbs.com/498f836caa6d2f5edd84d4c77a2d6a1e","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894322882,"type":1,"supId":0,"prevId":0,"content":"yes babe","text":"yes babe","html":"yes babe"}],"langContent":"EN"},{"id":894329299,"gmtCreate":1628807055811,"gmtModify":1676529857973,"author":{"id":"3579598708934903","authorId":"3579598708934903","name":"pfudor","avatar":"https://static.tigerbbs.com/992e0537af169325ff6d7110d0afa707","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3579598708934903","authorIdStr":"3579598708934903"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894329299","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894320010,"gmtCreate":1628806825830,"gmtModify":1676529857934,"author":{"id":"3577917241557928","authorId":"3577917241557928","name":"Andtendo","avatar":"https://static.tigerbbs.com/a36b92c865704901397ab4e190d5ad8a","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3577917241557928","authorIdStr":"3577917241557928"},"htmlText":"Like and comment please","listText":"Like and comment please","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894320010","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510171,"gmtCreate":1628809004882,"gmtModify":1663232298938,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894320010,"type":1,"supId":0,"prevId":0,"content":"Done. pls like back ","text":"Done. pls like back ","html":"Done. pls like back "}],"langContent":"EN"},{"id":894364431,"gmtCreate":1628806715523,"gmtModify":1676529857902,"author":{"id":"4087297789740060","authorId":"4087297789740060","name":"lingnh","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":6,"crmLevelSwitch":0,"idStr":"4087297789740060","authorIdStr":"4087297789740060"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894364431","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894366652,"gmtCreate":1628806184576,"gmtModify":1676529857831,"author":{"id":"3568883640417353","authorId":"3568883640417353","name":"losty","avatar":"https://static.tigerbbs.com/c49f1f2b3571ddd8e83ba724663f8f97","vip":1,"hat":"https://static.tigerbbs.com/0a8758340a08196056f8bc1e54805193","crmLevel":5,"crmLevelSwitch":1,"idStr":"3568883640417353","authorIdStr":"3568883640417353"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894366652","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509840,"gmtCreate":1628806729657,"gmtModify":1663232296236,"authorId":3570001951488746,"author":{"id":3570001951488746,"idStr":"3570001951488746","authorId":3570001951488746,"name":"Jaaaaaaa","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894366652,"type":1,"supId":0,"prevId":0,"content":"B","text":"B","html":"B"}],"langContent":"EN"},{"id":894388624,"gmtCreate":1628804720668,"gmtModify":1676529857583,"author":{"id":"3554799941327384","authorId":"3554799941327384","name":"liangwee888","avatar":"https://static.tigerbbs.com/5b494f711d74543d0aebd4ba8cd2e434","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3554799941327384","authorIdStr":"3554799941327384"},"htmlText":"comment","listText":"comment","text":"comment","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894388624","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509826,"gmtCreate":1628806579692,"gmtModify":1663232296030,"authorId":3577432235687566,"author":{"id":3577432235687566,"idStr":"3577432235687566","authorId":3577432235687566,"name":"MamaProfit","avatar":"https://static.tigerbbs.com/71c384811ff2abe860a7f1c6804b88b0","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894388624,"type":1,"supId":0,"prevId":0,"content":"no comment","text":"no comment","html":"no comment"}],"langContent":"EN"},{"id":894380045,"gmtCreate":1628803957287,"gmtModify":1676529857455,"author":{"id":"3576743360399762","authorId":"3576743360399762","name":"PooYen","avatar":"https://static.tigerbbs.com/90f2bad6620330727869f3a5a51a046a","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3576743360399762","authorIdStr":"3576743360399762"},"htmlText":"Please like. Thanks &nbsp;[Happy]&nbsp;[Happy]&nbsp;[Happy]&nbsp;","listText":"Please like. Thanks &nbsp;[Happy]&nbsp;[Happy]&nbsp;[Happy]&nbsp;","text":"Please like. Thanks [Happy] [Happy] [Happy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/894380045","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5510172,"gmtCreate":1628809016740,"gmtModify":1663232297336,"authorId":3582681835792049,"author":{"id":3582681835792049,"idStr":"3582681835792049","authorId":3582681835792049,"name":"Pplymm","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894380045,"type":1,"supId":0,"prevId":0,"content":"Done. pls like back ","text":"Done. pls like back ","html":"Done. pls like back "},{"id":5509856,"gmtCreate":1628806827200,"gmtModify":1663232295832,"authorId":3579903139528819,"author":{"id":3579903139528819,"idStr":"3579903139528819","authorId":3579903139528819,"name":"eddnesb","avatar":"https://static.tigerbbs.com/7cb1a44cae788badb83f540b30835814","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894380045,"type":1,"supId":5509604,"prevId":0,"content":"like <u>pls</u>","text":"like <u>pls</u>","html":"like <u>pls</u>"},{"id":5509604,"gmtCreate":1628803970081,"gmtModify":1663232294941,"authorId":3580070859233564,"author":{"id":3580070859233564,"idStr":"3580070859233564","authorId":3580070859233564,"name":"VenomJames","avatar":"https://static.tigerbbs.com/70886e65847996bcb0627151be63f811","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894380045,"type":1,"supId":0,"prevId":0,"content":"<u>Sure</u>","text":"<u>Sure</u>","html":"<u>Sure</u>"}],"langContent":"EN"},{"id":894315102,"gmtCreate":1628803577906,"gmtModify":1676529857341,"author":{"id":"3581487017513023","authorId":"3581487017513023","name":"J90","avatar":"https://static.tigerbbs.com/59b9bd5153d367d5ee88324bdf6c6003","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581487017513023","authorIdStr":"3581487017513023"},"htmlText":"Help","listText":"Help","text":"Help","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894315102","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509661,"gmtCreate":1628804740957,"gmtModify":1663232296145,"authorId":3554799941327384,"author":{"id":3554799941327384,"idStr":"3554799941327384","authorId":3554799941327384,"name":"liangwee888","avatar":"https://static.tigerbbs.com/5b494f711d74543d0aebd4ba8cd2e434","vip":1,"crmLevel":7,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894315102,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"},{"id":894315325,"gmtCreate":1628803566167,"gmtModify":1676529857341,"author":{"id":"3581487017513023","authorId":"3581487017513023","name":"J90","avatar":"https://static.tigerbbs.com/59b9bd5153d367d5ee88324bdf6c6003","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3581487017513023","authorIdStr":"3581487017513023"},"htmlText":"Yaaaa","listText":"Yaaaa","text":"Yaaaa","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/894315325","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5509737,"gmtCreate":1628805665894,"gmtModify":1635153050773,"authorId":3582021616632458,"author":{"id":3582021616632458,"idStr":"3582021616632458","authorId":3582021616632458,"name":"Xue91","avatar":"https://static.tigerbbs.com/4d9f9012cc2ef597a6ee7470e2cfb3e1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":894315325,"type":1,"supId":0,"prevId":0,"content":"Yahhhh","text":"Yahhhh","html":"Yahhhh"}],"langContent":"EN"},{"id":894318550,"gmtCreate":1628803206270,"gmtModify":1676529857290,"author":{"id":"3583140590641923","authorId":"3583140590641923","name":"Andrew210782","avatar":"https://static.tigerbbs.com/0e065afa93f953171dd0eb9aaebbe93b","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3583140590641923","authorIdStr":"3583140590641923"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894318550","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894331492,"gmtCreate":1628797567916,"gmtModify":1676529857095,"author":{"id":"3574813964437135","authorId":"3574813964437135","name":"June_C","avatar":"https://static.tigerbbs.com/ae77017e1795eeceab087663e5586137","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574813964437135","authorIdStr":"3574813964437135"},"htmlText":"Wiooo","listText":"Wiooo","text":"Wiooo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894331492","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":894394995,"gmtCreate":1628794114817,"gmtModify":1676529856942,"author":{"id":"4090758549041910","authorId":"4090758549041910","name":"MoreNmore","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"4090758549041910","authorIdStr":"4090758549041910"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/894394995","repostId":2158268958,"repostType":4,"repost":{"id":"2158268958","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1628781141,"share":"https://ttm.financial/m/news/2158268958?lang=&edition=fundamental","pubTime":"2021-08-12 23:12","market":"us","language":"en","title":"F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2158268958","media":"Benzinga","summary":"\n","content":"<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nF-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-08-12 23:12</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<ul>\n <li><b>F-star Therapeutics Inc</b>&nbsp;(NASDAQ:FSTX) has&nbsp;expanded its clinical development strategy&nbsp;for FS118 into checkpoint inhibitor naïve patients.</li>\n <li>The new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).</li>\n <li>FS118 is a bispecific antibody targeting LAG-3 and PD-L1.</li>\n <li>In addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.</li>\n <li>F-Star ended the quarter with cash and cash equivalents of $81.6 million.</li>\n <li><b>Price Action:</b>&nbsp;FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.</li>\n</ul>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FSTX":"F-star Therapeutics, Inc. "},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158268958","content_text":"F-star Therapeutics Inc (NASDAQ:FSTX) has expanded its clinical development strategy for FS118 into checkpoint inhibitor naïve patients.\nThe new study will start in 2H of 2021 and include biomarker enriched subsets of patients with non-small cell lung cancer (NSCLC) and diffuse large B-cell lymphoma (DLBCL).\nFS118 is a bispecific antibody targeting LAG-3 and PD-L1.\nIn addition to the expanded FS118 clinical strategy, F-star has three other ongoing programs.\nF-Star ended the quarter with cash and cash equivalents of $81.6 million.\nPrice Action: FSTX shares are up 4.92% at $6.93 during the market session on the last check Thursday.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":330,"commentSize":28,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}